BCMA-Targeted Bispecific T-Cell Engagers and Bispecific Monoclonal Antibodies in R/R MM

Source: Next-Generation Therapeutic Strategies for Relapsed/Refractory Multiple Myeloma: Targeting BCMA
Download Slideset
Download this slideset based on the content from a live stream CCO webinar from Suzanne Lentzsch, MD, PhD, on the latest data on BCMA x CD3 bispecific molecules for patients with relapsed/refractory multiple myeloma.
Suzanne Lentzsch, MD, PhD
Format: Microsoft PowerPoint (.ppt)
File Size: 2.81 MB
Released: September 10, 2021

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
GlaxoSmithKline
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings